RE:RE:RE:Small Sign: Clinical Trial For RVX-208 Soon To CommenceHi SanFran. Well put. I couldn't agree more.
It would not cost them any significant amount of money to communicate.
In terms of content it does not just have to be directly related to RVX or Zenith related activities. Themes could be about the larger context of BET inhibition and scientific papers related to this and the new theories related to inflammation and it's damaging effects across many diseases. All of this communication could be juxtaposed with and put in the context of the RVX and Zenith brands (e.g.information brought to you by...).
The available stories are almost unlimited and positive. All it requies is a creative mind. The blogs could be continuous.
Sources of information could come from proprietary research, published reasearch, books such as Grain Brain, etc all promoting the concept of BET inhibition and it's impact on diabetes mialitis, heart disease, various cancers, Alzheimers, etc.
Anyway, they should be smart enough to be dealing with this but obviously it is not on their agenda.
We really shouldn't be spending our time telling them what they need to do but I guess it's a matter of self preservation of assets.
It's a simple problem to solve - "RVX, please tell us your plan".
On another point one of the posters indicated, if I understood it correctly, that it would be very difficult to recruit for RE-MACE. Does this mean that very few of these types of patients exists? If so it implies that the market for rvx-208 may be extremely limited and this contradicts all of the evidence I've seen.
GLTA
toinv